Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Major depressive disorder | D003865 | EFO_0003761 | F22 | 7 | — | 1 | 2 | 1 | 11 |
Depressive disorder | D003866 | EFO_1002014 | F32.A | 6 | — | 1 | 2 | 1 | 10 |
Depression | D003863 | — | F33.9 | 4 | — | 1 | 1 | 1 | 7 |
Medically unexplained symptoms | D000071896 | — | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
Drug common name | Toludesvenlafaxine |
INN | toludesvenlafaxine |
Description | Toludesvenlafaxine, also formerly known as ansofaxine and sold under the brand name Ruoxinlin, is an antidepressant which is approved for the treatment of major depressive disorder in China. It is also under development for use in other countries like the United States. It is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) and was developed by Luye Pharma Group.
|
Classification | Small molecule |
Drug class | antianxiety, antidepressant inhibitor of norepinephrine and dopamine re-uptake |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Cc1ccc(C(=O)Oc2ccc(C(CN(C)C)C3(O)CCCCC3)cc2)cc1 |
PDB | — |
CAS-ID | 916918-84-8 |
RxCUI | — |
ChEMBL ID | CHEMBL4227736 |
ChEBI ID | — |
PubChem CID | 56955395 |
DrugBank | — |
UNII ID | A7CGH459FN (ChemIDplus, GSRS) |